RECRUITING

The Impact of Gender Affirming Hormone Therapy on Pain In Gender Minority Adults

Description

TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of surveys, quantitative sensory testing (QST), brain MRIs, and qualitative interviews. Following recruitment and consent, participants will complete baseline survey measures and will repeat those measures at 1 months, 3 month, 6 months, and 12 months. QST measures, brain MRIs, and Qualitative Interviews will be offered to participants in cohort (1) and will be completed at baseline and 12 months.

Conditions

PainGender Minority Individuals
Talk to us

Related Conditions:

PainGender Minority Individuals

Study Overview

On this page

Study Details

Study overview

TRANSPIRE is an observational study of \~200 individuals who (1) will be initiating gender-affirming hormone therapy (GHT) or (2) are gender minority individuals who do not use GHT. The primary outcome will be to identify how the presence of chronic pain changes overtime with GHT through the use of surveys, quantitative sensory testing (QST), brain MRIs, and qualitative interviews. Following recruitment and consent, participants will complete baseline survey measures and will repeat those measures at 1 months, 3 month, 6 months, and 12 months. QST measures, brain MRIs, and Qualitative Interviews will be offered to participants in cohort (1) and will be completed at baseline and 12 months.

The Impact of Gender Affirming Hormone Therapy on Pain In Gender Minority Adults

The Impact of Gender Affirming Hormone Therapy on Pain In Gender Minority Adults

Condition
Pain
Intervention / Treatment

-

Contacts and Locations

Kansas City

The University of Kansas Medical Center, Kansas City, Kansas, United States, 66160

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Informed consent provided by the participant
  • * Ages 18-50 years
  • * English speaking
  • * GM persons who have been deemed to be an appropriate medical candidate to take gender-affirming hormone therapy for gender incongruence -OR- GM persons who are not taking gender-affirming hormone therapy
  • * Inability to provide informed consent
  • * Age less than 18 years or greater than 50 years
  • * Severe physical impairment (e.g., blindness, deafness, paraplegia)
  • * Co-morbid medical conditions that may significantly impair physical functional status (e.g., history of non-skin malignancy, or autoimmune disorder)
  • * Pregnant or nursing
  • * Liver failure
  • * Self-reported liver cirrhosis
  • * Self-reported hepatitis
  • * Severe Cardiovascular disease (examples: history of myocardial infarction, unstable angina, severe coronary artery disease, congestive heart failure, or severe valvular abnormalities) that are self-reported by patient or by medical record
  • * Prisoner
  • * Current litigation for chronic pain
  • * Current disability proceedings
  • * Active psychotic or suicidal symptoms
  • * Current drug or alcohol use disorder
  • * History of gonadectomy surgery

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Kansas Medical Center,

Andrea L Chadwick, MD, MSc, FASA, PRINCIPAL_INVESTIGATOR, The University of Kansas Medical Center

Study Record Dates

2029-09-16